Ignite Creation Date:
2024-05-06 @ 10:10 AM
Last Modification Date:
2024-10-26 @ 12:26 PM
Study NCT ID:
NCT03182257
Status:
TERMINATED
Last Update Posted:
2019-09-13
First Post:
2017-05-19
Brief Title:
Study of ONO-7579 in Patients With Advanced Solid Tumors NTRK Gene Fusion Positive Advanced Solid Tumors
Sponsor:
Ono Pharmaceutical Co Ltd
Organization:
Ono Pharmaceutical Co Ltd
Study Overview
Official Title:
An Open-label Multi-center Dose-escalation and Expansion Study to Evaluate the Safety and Efficacy of ONO-7579 in Patients With Advanced Solid Tumors NTRK Gene Fusion Positive Advanced Solid Tumors
Status:
TERMINATED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was stopped for commercial reasons No safety issues were reported
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ONTRK
Brief Summary:
This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions
Detailed Description:
The trial was designed to be a Phase 12 trial but was terminated without progressing to Phase 2
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None